<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02044172</url>
  </required_header>
  <id_info>
    <org_study_id>HTA96/20/99</org_study_id>
    <secondary_id>20141297</secondary_id>
    <nct_id>NCT02044172</nct_id>
    <nct_alias>NCT00632983</nct_alias>
  </id_info>
  <brief_title>Prostate Testing for Cancer and Treatment</brief_title>
  <acronym>ProtecT</acronym>
  <official_title>The ProtecT Trial - Evaluating the Effectiveness of Treatments for Clinically Localised Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bristol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radical prostatectomy is surgery to remove the entire prostate. Radiation therapy
      uses high-energy x-rays or other types of radiation to kill tumor cells. Sometimes the tumor
      may not need treatment until it progresses. In this case, active surveillance may be
      sufficient. It is not yet known which treatment regimen is more effective for localized
      prostate cancer.

      PURPOSE: This randomized phase III trial is studying active monitoring to see how well it
      works compared with radical prostatectomy or radiation therapy in treating patients with
      localized prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To assess survival of patients with localized prostate cancer at 10 years and 15 years
           after treatment.

        -  To investigate disease progression (i.e., biochemical and clinical), treatment
           complications, and lower urinary tract symptoms in these patients.

        -  To investigate the psychosocial impact of cancer detection and treatment on these
           patients, including generic health status, quality of life, and sexual function.

        -  To estimate the resource use and costs of detection, treatment, and follow-up.

        -  To compare costs and outcomes of treatment in terms of survival and health-related
           quality of life.

        -  To collect samples suitable for basic science research (ProMPT study).

      OUTLINE: This is a multicenter study. Patients are stratified by age (50-55 vs 56-59 vs 60-65
      vs 66-69 years), Gleason score (6, 7, 8-10), and average result of recruitment and first
      biopsy prostate-specific antigen (PSA) tests (&lt; 6 vs 6-9.9 vs â‰¥ 10 ng/mL). Patients are
      randomized or select a treatment to be followed up in a cohort study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2001</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease specific mortality</measure>
    <time_frame>Median 10 years follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Median 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>Median 10 years</time_frame>
    <description>Metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment complications</measure>
    <time_frame>Median 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health status</measure>
    <time_frame>Median 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological state</measure>
    <time_frame>Median 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>Median 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
    <time_frame>Median 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource use</measure>
    <time_frame>Median 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100000</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radical prostatectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radical prostatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conformal radiation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conformal radiation therapy External beam radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active monitoring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active monitoring of prostate specific antigen levels and disease surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical prostatectomy</intervention_name>
    <description>radical prostatectomy</description>
    <arm_group_label>Radical prostatectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conformal radiation therapy</intervention_name>
    <description>Conformal radiation therapy, external beam</description>
    <arm_group_label>Conformal radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active monitoring</intervention_name>
    <description>Active monitoring of Prostate specific antigen levels and disease surveillance</description>
    <arm_group_label>Active monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Fit for the treatments and estimates life expectancy of 10 years Registration with eligible
        primary care practice

        Exclusion Criteria:

        Unable to give written informed consent. Concomitant or past malignancy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Freddie C Hamdy</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrokes' Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.bristol.ac.uk/population-health-sciences/projects/protect/</url>
    <description>Project website</description>
  </link>
  <reference>
    <citation>Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer. 2010 Nov;46(17):3095-101. doi: 10.1016/j.ejca.2010.09.016.</citation>
    <PMID>21047592</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Treatment</keyword>
  <keyword>Screening</keyword>
  <keyword>Surgery</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Active monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

